Targeting a Mimotope Vaccine to Activating Fcγ Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice
Abstract A major challenge for inducing antitumor immune responses with native or modified tumor/self-Ags in tumor-bearing hosts relates to achieving efficient uptake and processing by dendritic cells (DCs) to activate immune effector cells and limit the generation of regulatory T cell activity. We...
Saved in:
Published in | The Journal of immunology (1950) Vol. 183; no. 10; pp. 6808 - 6818 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
15.11.2009
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
A major challenge for inducing antitumor immune responses with native or modified tumor/self-Ags in tumor-bearing hosts relates to achieving efficient uptake and processing by dendritic cells (DCs) to activate immune effector cells and limit the generation of regulatory T cell activity. We analyzed the ability of therapeutic DC vaccines expressing a CD166 cross-reactive mimotope of the GD2 ganglioside, 47-LDA, to selectively expand adoptively transferred, tumor-specific T cells in NXS2 neuroblastoma tumor-bearing syngeneic mice. Before the adoptive cell transfer and DC vaccination, the tumor-bearing mice were lymphodepleted by nonmyeloablative total body irradiation or a myeloablative regimen that required bone marrow transplantation. The 47-LDA mimotope was presented to DCs either as a linear polypeptide in conjunction with universal Th epitopes or as a fusion protein with the murine IgG2a Fc fragment (47-LDA-Fcγ2a) to deliver the antigenic cassette to the activating Fcγ receptors. We demonstrate that immunization of adoptively transferred T cells in tumor-bearing mice with the 47-LDA mimotope expressed in the context of the activating Fc fusion protein induced higher levels of antitumor immune responses and protection than the 47-LDA polypeptide-DC vaccine. The antitumor efficacy of the therapeutic 47-LDA-Fcγ2a-DC vaccine was comparable to that achieved by a virotherapy-associated cancer vaccine using a recombinant oncolytic vaccinia virus expressing the 47-LDA-Fcγ2a fusion protein. The latter treatment, however, did not require total body irradiation or adoptive cell transfer and resulted in induction of antitumor immune responses in the setting of established tolerance, paving the way for testing novel anticancer treatment strategies. |
---|---|
AbstractList | Abstract
A major challenge for inducing antitumor immune responses with native or modified tumor/self-Ags in tumor-bearing hosts relates to achieving efficient uptake and processing by dendritic cells (DCs) to activate immune effector cells and limit the generation of regulatory T cell activity. We analyzed the ability of therapeutic DC vaccines expressing a CD166 cross-reactive mimotope of the GD2 ganglioside, 47-LDA, to selectively expand adoptively transferred, tumor-specific T cells in NXS2 neuroblastoma tumor-bearing syngeneic mice. Before the adoptive cell transfer and DC vaccination, the tumor-bearing mice were lymphodepleted by nonmyeloablative total body irradiation or a myeloablative regimen that required bone marrow transplantation. The 47-LDA mimotope was presented to DCs either as a linear polypeptide in conjunction with universal Th epitopes or as a fusion protein with the murine IgG2a Fc fragment (47-LDA-Fcγ2a) to deliver the antigenic cassette to the activating Fcγ receptors. We demonstrate that immunization of adoptively transferred T cells in tumor-bearing mice with the 47-LDA mimotope expressed in the context of the activating Fc fusion protein induced higher levels of antitumor immune responses and protection than the 47-LDA polypeptide-DC vaccine. The antitumor efficacy of the therapeutic 47-LDA-Fcγ2a-DC vaccine was comparable to that achieved by a virotherapy-associated cancer vaccine using a recombinant oncolytic vaccinia virus expressing the 47-LDA-Fcγ2a fusion protein. The latter treatment, however, did not require total body irradiation or adoptive cell transfer and resulted in induction of antitumor immune responses in the setting of established tolerance, paving the way for testing novel anticancer treatment strategies. |
Author | Gil, Margaret Kozbor, Danuta Bieniasz, Magdalena Bambach, Barbara J. Rokita, Hanna Wierzbicki, Andrzej |
Author_xml | – sequence: 1 givenname: Margaret surname: Gil fullname: Gil, Margaret – sequence: 2 givenname: Magdalena surname: Bieniasz fullname: Bieniasz, Magdalena – sequence: 3 givenname: Andrzej surname: Wierzbicki fullname: Wierzbicki, Andrzej – sequence: 4 givenname: Barbara J. surname: Bambach fullname: Bambach, Barbara J. – sequence: 5 givenname: Hanna surname: Rokita fullname: Rokita, Hanna – sequence: 6 givenname: Danuta surname: Kozbor fullname: Kozbor, Danuta |
BookMark | eNo1kEtOwzAQhi0EEm1hz9J7lDLOq_Gy9AFIrUAQ2EaOPalcNXZkpyBuwV24B2ciKWU1o3n8_8w3JKfGGiTkisE4hpjfbHVd743djYEDRGl8QgYsSSBIU0hPyQAgDAM2SSfnZOj9FgBSCOMB-cqF22CrzYYKuta1bW2D9E1IqQ3S1tKpbPW7OAws5c83fUaJTWudp4u6sR_YJXM0yulWSzrD3c73W09O10hfGpS66uvz7Jrmh3Yn4BtrPHqqDc33tXXBLQrXG6y1xAtyVomdx8tjHJHX5SKf3Qerx7uH2XQVyDBL2kBmEPEkKWPFlOKJZFVZxTxKSjYpmVSV4ipJs4yjAISo7J4VgscMMhFWPFQsGhH405XOeu-wKpruZuE-CwZFT7T4J1ociUa_qvVvmg |
CitedBy_id | crossref_primary_10_3390_vaccines9010001 crossref_primary_10_3390_children8060482 crossref_primary_10_2174_1568026619666190904163524 crossref_primary_10_1016_j_vaccine_2016_12_035 crossref_primary_10_1002_emmm_201201379 crossref_primary_10_1007_s12026_012_8300_z crossref_primary_10_1038_bjc_2011_429 crossref_primary_10_1073_pnas_1220580110 crossref_primary_10_4049_jimmunol_1400201 crossref_primary_10_1586_erv_11_105 crossref_primary_10_1016_j_omto_2019_06_003 crossref_primary_10_1155_2018_8097398 crossref_primary_10_2217_imt_11_169 crossref_primary_10_1038_mto_2016_34 crossref_primary_10_3390_immuno3020009 crossref_primary_10_1016_j_vaccine_2014_07_050 crossref_primary_10_1080_19420862_2021_1982447 crossref_primary_10_3390_v10090455 crossref_primary_10_1016_j_jddst_2023_105009 crossref_primary_10_1007_s10330_010_0707_1 crossref_primary_10_2217_fvl_10_58 |
Cites_doi | 10.1158/0008-5472.CAN-07-6012 10.1182/blood-2006-06-027136 10.1084/jem.20050810 10.1084/jem.20011925 10.1084/jem.189.2.371 10.4049/jimmunol.168.5.2240 10.1172/JCI31202 10.1084/jem.194.12.1767 10.1038/nm1039 10.1158/0008-5472.CAN-06-3974 10.1182/blood-2005-07-2737 10.1152/ajplung.00187.2002 10.1146/annurev.iy.13.040195.001343 10.1016/j.coi.2007.02.004 10.1158/0008-5472.CAN-05-1299 10.4049/jimmunol.164.3.1625 10.1126/science.1078231 10.1128/jvi.62.3.866-874.1988 10.1016/j.immuni.2005.11.010 10.1073/pnas.0502547102 10.1084/jem.20020338 10.2217/fon.09.6 10.4049/jimmunol.174.12.7654 10.4049/jimmunol.170.9.4427 10.1182/blood-2006-03-011353 10.1158/0008-5472.CAN-04-2164 10.1038/ni1162 10.1038/gt.2008.72 10.1002/eji.200838197 10.1056/NEJMoa0800251 10.1182/blood.V91.5.1706.1706_1706_1715 10.1084/jem.20041057 10.1007/s00262-003-0435-2 10.1084/jem.20062545 10.1158/0008-5472.CAN-06-2871 10.4049/jimmunol.177.1.177 10.1146/annurev.immunol.19.1.275 10.1097/00002371-200011000-00005 10.1093/annonc/mdj138 10.1182/blood-2007-09-114371 10.1172/JCI6909 10.1111/j.1600-065X.2007.00575.x 10.1186/1476-4598-2-22 10.1073/pnas.0501953102 10.1038/nri1256 10.4049/jimmunol.181.9.6644 10.1073/pnas.0500014102 10.1084/jem.189.5.803 10.1016/S0167-5699(99)01547-9 10.1111/j.1348-0421.1997.tb01926.x 10.1007/s00262-007-0390-4 10.1172/JCI24772 10.1073/pnas.202491499 10.1126/science.1118948 10.4049/jimmunol.160.11.5676 10.1002/ijc.23692 10.4049/jimmunol.178.5.2883 10.1158/0008-5472.CAN-07-6818 10.1007/s00262-007-0289-0 10.1158/0008-5472.CAN-05-0141 10.1016/j.semcancer.2005.11.005 10.1038/ni1059 10.1172/JCI17349 10.1038/sj.cdd.4402247 10.1158/0008-5472.CAN-06-3593 10.1016/j.cell.2008.05.009 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.4049/jimmunol.0900364 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1550-6606 |
EndPage | 6818 |
ExternalDocumentID | 10_4049_jimmunol_0900364 |
GroupedDBID | --- -~X .55 18M 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 79B 85S AARDX AAYXX ABCQX ABEFU ABJNI ABOCM ABPPZ ACGFO ACGFS ACIWK ACNCT ACPRK ADBBV ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AHWXS AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION D0L DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 K-O KQ8 L7B MVM OK1 P0W P2P PQQKQ R.V RHF RHI RZQ SJN TR2 TWZ W8F WH7 WOQ X7M XJT XSW XTH YHG ZE2 ZGI |
ID | FETCH-LOGICAL-c285t-c803955b4d1dd95c1fbf4935b17b1cdfd9d56889ea0e03b602aa94108a2f92d13 |
ISSN | 0022-1767 |
IngestDate | Fri Aug 23 10:45:30 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c285t-c803955b4d1dd95c1fbf4935b17b1cdfd9d56889ea0e03b602aa94108a2f92d13 |
OpenAccessLink | https://www.jimmunol.org/content/jimmunol/183/10/6808.full.pdf |
PageCount | 11 |
ParticipantIDs | crossref_primary_10_4049_jimmunol_0900364 |
PublicationCentury | 2000 |
PublicationDate | 2009-11-15 |
PublicationDateYYYYMMDD | 2009-11-15 |
PublicationDate_xml | – month: 11 year: 2009 text: 2009-11-15 day: 15 |
PublicationDecade | 2000 |
PublicationTitle | The Journal of immunology (1950) |
PublicationYear | 2009 |
References | 2023010202221205700_R9 2023010202221205700_R8 2023010202221205700_R3 2023010202221205700_R20 2023010202221205700_R64 2023010202221205700_R2 2023010202221205700_R21 2023010202221205700_R65 2023010202221205700_R1 2023010202221205700_R62 2023010202221205700_R63 2023010202221205700_R7 2023010202221205700_R60 2023010202221205700_R6 2023010202221205700_R61 2023010202221205700_R5 2023010202221205700_R4 2023010202221205700_R17 2023010202221205700_R18 2023010202221205700_R15 2023010202221205700_R59 2023010202221205700_R16 2023010202221205700_R13 2023010202221205700_R57 2023010202221205700_R14 2023010202221205700_R58 2023010202221205700_R11 2023010202221205700_R55 2023010202221205700_R12 2023010202221205700_R56 2023010202221205700_R19 2023010202221205700_R31 2023010202221205700_R32 2023010202221205700_R30 2023010202221205700_R28 2023010202221205700_R29 2023010202221205700_R26 2023010202221205700_R27 2023010202221205700_R24 2023010202221205700_R68 2023010202221205700_R25 2023010202221205700_R69 2023010202221205700_R22 2023010202221205700_R66 2023010202221205700_R23 2023010202221205700_R67 2023010202221205700_R42 2023010202221205700_R43 2023010202221205700_R40 2023010202221205700_R41 2023010202221205700_R39 2023010202221205700_R37 2023010202221205700_R38 2023010202221205700_R35 2023010202221205700_R36 2023010202221205700_R33 2023010202221205700_R34 2023010202221205700_R53 2023010202221205700_R10 2023010202221205700_R54 2023010202221205700_R51 2023010202221205700_R52 2023010202221205700_R50 2023010202221205700_R48 2023010202221205700_R49 2023010202221205700_R46 2023010202221205700_R47 2023010202221205700_R44 2023010202221205700_R45 |
References_xml | – ident: 2023010202221205700_R9 doi: 10.1158/0008-5472.CAN-07-6012 – ident: 2023010202221205700_R32 doi: 10.1182/blood-2006-06-027136 – ident: 2023010202221205700_R68 doi: 10.1084/jem.20050810 – ident: 2023010202221205700_R37 – ident: 2023010202221205700_R54 doi: 10.1084/jem.20011925 – ident: 2023010202221205700_R23 doi: 10.1084/jem.189.2.371 – ident: 2023010202221205700_R56 doi: 10.4049/jimmunol.168.5.2240 – ident: 2023010202221205700_R1 doi: 10.1172/JCI31202 – ident: 2023010202221205700_R14 doi: 10.1084/jem.194.12.1767 – ident: 2023010202221205700_R60 doi: 10.1038/nm1039 – ident: 2023010202221205700_R35 doi: 10.1158/0008-5472.CAN-06-3974 – ident: 2023010202221205700_R4 doi: 10.1182/blood-2005-07-2737 – ident: 2023010202221205700_R40 doi: 10.1152/ajplung.00187.2002 – ident: 2023010202221205700_R47 doi: 10.1146/annurev.iy.13.040195.001343 – ident: 2023010202221205700_R8 doi: 10.1016/j.coi.2007.02.004 – ident: 2023010202221205700_R62 doi: 10.1158/0008-5472.CAN-05-1299 – ident: 2023010202221205700_R38 doi: 10.4049/jimmunol.164.3.1625 – ident: 2023010202221205700_R69 doi: 10.1126/science.1078231 – ident: 2023010202221205700_R44 doi: 10.1128/jvi.62.3.866-874.1988 – ident: 2023010202221205700_R46 doi: 10.1016/j.immuni.2005.11.010 – ident: 2023010202221205700_R17 doi: 10.1073/pnas.0502547102 – ident: 2023010202221205700_R25 doi: 10.1084/jem.20020338 – ident: 2023010202221205700_R2 doi: 10.2217/fon.09.6 – ident: 2023010202221205700_R50 doi: 10.4049/jimmunol.174.12.7654 – ident: 2023010202221205700_R13 doi: 10.4049/jimmunol.170.9.4427 – ident: 2023010202221205700_R49 doi: 10.1182/blood-2006-03-011353 – ident: 2023010202221205700_R27 doi: 10.1158/0008-5472.CAN-04-2164 – ident: 2023010202221205700_R59 doi: 10.1038/ni1162 – ident: 2023010202221205700_R34 doi: 10.1038/gt.2008.72 – ident: 2023010202221205700_R66 doi: 10.1002/eji.200838197 – ident: 2023010202221205700_R52 doi: 10.1056/NEJMoa0800251 – ident: 2023010202221205700_R36 doi: 10.1182/blood.V91.5.1706.1706_1706_1715 – ident: 2023010202221205700_R42 doi: 10.1084/jem.20041057 – ident: 2023010202221205700_R51 doi: 10.1007/s00262-003-0435-2 – ident: 2023010202221205700_R26 doi: 10.1084/jem.20062545 – ident: 2023010202221205700_R33 doi: 10.1158/0008-5472.CAN-06-2871 – ident: 2023010202221205700_R43 doi: 10.4049/jimmunol.177.1.177 – ident: 2023010202221205700_R20 doi: 10.1146/annurev.immunol.19.1.275 – ident: 2023010202221205700_R30 doi: 10.1097/00002371-200011000-00005 – ident: 2023010202221205700_R3 doi: 10.1093/annonc/mdj138 – ident: 2023010202221205700_R10 doi: 10.1182/blood-2007-09-114371 – ident: 2023010202221205700_R16 doi: 10.1172/JCI6909 – ident: 2023010202221205700_R5 doi: 10.1111/j.1600-065X.2007.00575.x – ident: 2023010202221205700_R64 doi: 10.1186/1476-4598-2-22 – ident: 2023010202221205700_R24 doi: 10.1073/pnas.0501953102 – ident: 2023010202221205700_R61 doi: 10.1038/nri1256 – ident: 2023010202221205700_R28 doi: 10.4049/jimmunol.181.9.6644 – ident: 2023010202221205700_R18 doi: 10.1073/pnas.0500014102 – ident: 2023010202221205700_R15 doi: 10.1084/jem.189.5.803 – ident: 2023010202221205700_R58 doi: 10.1016/S0167-5699(99)01547-9 – ident: 2023010202221205700_R39 doi: 10.1111/j.1348-0421.1997.tb01926.x – ident: 2023010202221205700_R11 doi: 10.1007/s00262-007-0390-4 – ident: 2023010202221205700_R55 doi: 10.1172/JCI24772 – ident: 2023010202221205700_R67 doi: 10.1073/pnas.202491499 – ident: 2023010202221205700_R19 doi: 10.1126/science.1118948 – ident: 2023010202221205700_R45 doi: 10.4049/jimmunol.160.11.5676 – ident: 2023010202221205700_R53 doi: 10.1002/ijc.23692 – ident: 2023010202221205700_R63 doi: 10.4049/jimmunol.178.5.2883 – ident: 2023010202221205700_R48 doi: 10.1158/0008-5472.CAN-07-6818 – ident: 2023010202221205700_R57 – ident: 2023010202221205700_R41 doi: 10.1007/s00262-007-0289-0 – ident: 2023010202221205700_R65 doi: 10.1158/0008-5472.CAN-05-0141 – ident: 2023010202221205700_R7 doi: 10.1016/j.semcancer.2005.11.005 – ident: 2023010202221205700_R29 – ident: 2023010202221205700_R31 doi: 10.1038/ni1059 – ident: 2023010202221205700_R22 doi: 10.1172/JCI17349 – ident: 2023010202221205700_R21 doi: 10.1038/sj.cdd.4402247 – ident: 2023010202221205700_R12 doi: 10.1158/0008-5472.CAN-06-3593 – ident: 2023010202221205700_R6 doi: 10.1016/j.cell.2008.05.009 |
SSID | ssj0006024 |
Score | 2.1328986 |
Snippet | Abstract
A major challenge for inducing antitumor immune responses with native or modified tumor/self-Ags in tumor-bearing hosts relates to achieving efficient... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 6808 |
Title | Targeting a Mimotope Vaccine to Activating Fcγ Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice |
Volume | 183 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIhAXBAuIf_lADyhKyY-d2MdtaXe1UhGHLuqtSmwHLdqm1dIe6FPwLrwHb8F7MGPnrxVILJe0ctxJ6_k6Mx7PDyFvhE6SoogDn6WwXWVSpX4OVrOfZ8wIneaS2ZL50w_J2QU7n_N5r_erE7W03eQDtftjXsn_cBXGgK-YJXsDzjZEYQDeA3_hChyG67_x2IZx2zRDb4qLvlob71Om8LAcjcoT5ZqXwYSJ6o_G_WGMdqJZ2xY74-XatkgDmVNq2_HAG5mrK1vy4SNW_XfN6Qscfy_60dCb2Qno8se4WhvK5c22y9W1P4Q_DD5mWoXS1fZum3nmilNgNoqr-tS3Z2tBxxNx6tzRdevd1n2P8YBfd-7eZwyALltdAlp9l18q13wbozN35kvrnV3mmWt1VR2reOeDPTeHxHw_l-jZSTsIU9e7Y2Aqac1h75sEyb44j7u4DTrSGduMdDR9IpzoP9QiDHZNqEWqNRkE6O11tdb3C3YfKNImvBE2VkhjUVNYVBRukdtRKjn6CE7nbSRSEkSsLmqPv9CdpiOFd4ffoWM9dcyg2QNyv-IlPXFgfEh6pjwmd1xH02_H5O60itV4RL436KQZrdFJK3TSzYq26KQT9fMHbZBJa2TSBpnUIhM_ZZFJa2RSQKZHZ_Y2bXBJL0u6h0uKuHxMLibj2ejMr_p_-CoSfOMrEcSS85zpUGvJVVjkBZMxz8M0D5UutNQ8EUKaLDBBDCImyjLJwkBkUSEjHcZPyFG5Ks1TQhlQUangmY4kmODwmhmuCiYSmQol9TPytl7XxdqVeVn8jYvPbzD3BbnXgvklOdpcb80rsGI3-WuLgd-AZqAM |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+a+Mimotope+Vaccine+to+Activating+Fc%CE%B3+Receptors+Empowers+Dendritic+Cells+to+Prime+Specific+CD8%2B+T+Cell+Responses+in+Tumor-Bearing+Mice&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Gil%2C+Margaret&rft.au=Bieniasz%2C+Magdalena&rft.au=Wierzbicki%2C+Andrzej&rft.au=Bambach%2C+Barbara+J.&rft.date=2009-11-15&rft.issn=0022-1767&rft.eissn=1550-6606&rft.volume=183&rft.issue=10&rft.spage=6808&rft.epage=6818&rft_id=info:doi/10.4049%2Fjimmunol.0900364&rft.externalDBID=n%2Fa&rft.externalDocID=10_4049_jimmunol_0900364 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon |